New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 20, 2012
10:00 EDTCLNE, PANW, SIX, JNJ, COH, AET, TDC, RLGY, ISRG, CFN, UNH, MPLX, COV, BSX, MDCOOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aetna (AET) initiated with a Buy at Lazard Capital... Boston Scientific (BSX) initiated with a Buy at Stifel Nicolaus... CareFusion (CFN) initiated with a Buy at Stifel Nicolaus... Coach (COH) initiated with an Outperform at Wells Fargo... Covidien (COV) initiated with a Buy at Brean Capital... Intuitive Surgical (ISRG) initiated with a Hold at Stifel Nicolaus... Johnson & Johnson (JNJ) initiated with a Hold at Stifel Nicolaus... MPLX (MPLX) initiated with a Neutral at UBS... Realogy (RLGY) initiated with a Neutral at Goldman... The Medicines Co. (MDCO) initiated with an Outperform at Oppenheimer... UnitedHealth (UNH) initiated with a Buy at Lazard Capital... Teradata (TDC) initiated with an Outperform at Credit Suisse... Six Flags (SIX) initiated with a Neutral at Longbow... Palo Alto (PANW) initiated with a Neutral at Nomura... Clean Energy (CLNE) initiated with a Buy at Dougherty.
News For AET;BSX;CFN;COH;COV;ISRG;JNJ;MPLX;RLGY;MDCO;UNH;TDC;SIX;PANW;CLNE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
May 14, 2015
09:41 EDTJNJ, BSXLeerink medical devices analyst holds a cardiology luncheon meeting
Subscribe for More Information
08:52 EDTPANWPalo Alto Q3 checks positive, says Stephens
Stephens said its checks have come back positive during Palo Alto's Q3 have been positive, leading the firm to expect the company's results to top consensus expectations. Stephens keeps its Overweight rating and $170 price target on Palo Alto shares.
08:21 EDTPANWFinjan says patent suits ongoing with numerous cybersecurity companies
Finjan (FNJN) said it has an active Markman Hearing schedule with two Markman Hearings already concluded in favor of the company and two additional Markman Hearings to be held in Q2. The company has a two-week trial against Blue Coat set to commence on July 20. Finjan has patent infringement lawsuits against FireEye (FEYE), BlueCoat, Proofpoint (PFPT), Sophos, Symantec (SYMC), and Palo Alto Networks (PANW) relating to, collectively, more than 20 patents in the Finjan portfolio. Subsequent to the quarter end, Finjan entered into a negotiated license agreement with F-Secure Corporation, a company incorporated in Finland. The agreement provides for F-Secure to pay Finjan the sum of $1M in cash, to be paid in two installments, consisting of $700,000 which was received on April 22 and $300,000 on or before March 31, 2016. The agreement also provides for the assignment by F-Secure to Finjan of two patents, U.S. Patent Nos. 8,474,048 and 7,749,991.
07:33 EDTUNHUnitedHealth would consider Optum spinoff if benefits erode, says UBS
Subscribe for More Information
06:33 EDTCOHCoach initiated with a Neutral at Wedbush
Target $37.
May 13, 2015
17:50 EDTJNJPharmacyclics to showcase new 'promising' Imbruvica data at ASCO
Pharmacyclics announced that ibrutinib, also known as Imbruvica, single-agent and combination data will be featured in seven oral and poster sessions at the 51st American Society of Clinical Oncology, ASCO, Annual Meeting being held May 29-June 2 in Chicago, IL. According to a statement from ASCO, Imbruvica data will also be included in the official press program during the meeting for the second time in two years. Imbruvica is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a Johnson & Johnson (JNJ) subsidiary. Data being presented include, among others, an oral presentation from the Phase III HELIOS study of ibrutinib in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia, a poster presentation of ibrutinib in steroid-dependent or refractory chronic graft-versus-host-disease as well as a dose adherence analysis of ibrutinib 420 mg administered to previously treated CLL patients. "We look forward to sharing promising data at this year's ASCO that examines the use of Imbruvica across a broad range of hematologic disease settings from our clinical studies," said Danelle James, M.D., M.S., Head of Oncology at Pharmacyclics.
15:26 EDTTDCMatrix urges Teradata to pursue sale, Bloomberg reports
Subscribe for More Information
13:53 EDTTDCMatrix urges Teradata to pursue sale, Bloomberg reports
Subscribe for More Information
11:08 EDTCLNEOptions with decreasing implied volatility
Subscribe for More Information
10:18 EDTAETAnalyst says sell Humana amid 'wishful' takeover speculation
Subscribe for More Information
07:31 EDTBSXHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.
May 12, 2015
13:03 EDTAETAetna repeats view of FY15 operating EPS $7.20-$7.40, consensus $7.38
Subscribe for More Information
11:53 EDTAETAnalyst predicts large transaction 'imminent' for Aetna
Subscribe for More Information
10:04 EDTAETHigh option volume stocks
Subscribe for More Information
10:01 EDTISRGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:53 EDTAETAetna merger with Cigna or Humana likely 'imminent,' says Leerink
Subscribe for More Information
09:33 EDTMPLXMarathon Petroleum repeats FY15 capital expenditure view of $2.5B
Subscribe for More Information
07:50 EDTSIXWells Fargo to hold a conference
Subscribe for More Information
05:34 EDTISRGIntuitive Surgical initiated with a Neutral at Piper Jaffray
Piper Jaffray analyst Matt O'Brien started shares of Intuitive Surgical with a Neutral rating and $505 price target. O'Brien calls the stock "simply too expensive" relative to expected sales and earnings, but admits Intuitive's robotic surgical technology will likely dominate the market in the coming years. Further, the analyst thinks the company's da Vinci Prostatectomy and da Vinci Hysterectomy procedures could contract amid new diagnostic tests and insurance pushback. The stock closed yesterday up $2.05 to $496.37.
05:23 EDTBSXNevro announces filing of petitions for inter partes review by Boston Scientific
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use